Heron Therapeutics, Inc.
Here’s whether Heron Therapeutics, Inc. (HRTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-10.31% over 10 days); RSI 15 — oversold; weak 1-year return of -75.9%; 3-month momentum negative (-63.0%); rising volume on a downtrend (distribution, 1.55x avg). Currently 79.8% off its 52-week high. Score: -7/7.
HRTX is trading below its 200-day MA ($0.92) — a key warning sign the longer-term trend is under pressure. An RSI of 15.3 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -75.9% compares to +20.5% for SPY (trailed the market by 96.4%). The current 79.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.